Yes, cystic fibrosis (CF) is a recessive genetic condition, specifically autosomal recessive. This means a child must inherit two faulty copies of the responsible gene, one from each parent, to develop the disease. A person who carries only one faulty copy is called a carrier and typically has no symptoms at all.
What Autosomal Recessive Means
“Autosomal” refers to the fact that the gene sits on one of the 22 non-sex chromosomes, so CF affects males and females equally. “Recessive” means the condition only appears when both copies of the gene are mutated. Everyone carries two copies of every autosomal gene. If at least one copy works normally, it produces enough functional protein to keep the body running, so carriers stay healthy.
This is why CF often seems to appear “out of nowhere.” Two parents who feel perfectly fine can each silently carry one faulty copy. Neither knows they’re a carrier until a child is born with the condition or genetic testing reveals it.
The Odds When Both Parents Are Carriers
When two carriers have a child, every pregnancy carries the same set of probabilities:
- 25% chance the child inherits two normal copies and is completely unaffected.
- 50% chance the child inherits one faulty copy and one normal copy, becoming a carrier like the parents, with no symptoms.
- 25% chance the child inherits two faulty copies and has cystic fibrosis.
These odds reset with each pregnancy. Having one child with CF does not change the probability for the next child. If only one parent is a carrier, none of their children will have CF, though each child has a 50% chance of being a carrier themselves.
The Gene Behind CF
CF is caused by mutations in a gene called CFTR, which provides the blueprint for a protein that works as a chloride channel on cell surfaces. In the lungs, this channel moves chloride ions out of cells. Once outside, chloride attracts a thin layer of water. That water layer keeps mucus wet and slippery, allowing tiny hair-like structures on lung cells (called cilia) to sweep mucus up and out of the airways.
When the CFTR protein is missing, misshapen, or produced in insufficient quantities, chloride gets trapped inside cells. Without chloride drawing water to the surface, mucus becomes thick and sticky. It flattens the cilia so they can no longer sweep effectively. This dehydrated mucus clogs airways, pancreatic ducts, and other passageways, producing the hallmark symptoms of CF: chronic lung infections, difficulty digesting food, and progressive lung damage.
More Than 2,000 Mutations, One Dominant
Scientists have identified over 2,000 different mutations in the CFTR gene, but they aren’t equally common. One mutation, called F508del, accounts for roughly two-thirds of all CF-causing gene copies worldwide. A person with CF may carry two copies of F508del, or one copy of F508del paired with a different mutation on the other chromosome. The remaining mutations each account for small percentages: G542X at about 2.6%, N1303K at 1.6%, and G551D at 1.5%, for example.
The specific mutations matter for treatment. Modern therapies called CFTR modulators work by fixing or boosting the defective protein. The most widely used combination (sold as Trikafta) is approved for people ages 2 and older who have at least one mutation that still produces some CFTR protein. It works by helping the misfolded protein reach the cell surface in the correct shape, then holding the chloride channel open so ions can flow through. For people who carry two mutations that produce no protein at all, these modulators currently have limited benefit, which is why knowing your exact mutations is clinically important.
Carrier Screening
Because carriers have no symptoms, the only way to know your status before having a child is through genetic testing. The American College of Obstetricians and Gynecologists recommends that CF carrier screening be offered to all women who are considering pregnancy or are currently pregnant. Ideally, screening happens before conception so couples have time to understand their options. If one partner tests positive as a carrier, the other partner is then tested. Only when both are carriers does the 25% risk apply.
Carrier frequency varies by ethnic background. Roughly 1 in 29 people of Northern European descent carry a CFTR mutation. The rate is lower in other populations but not zero, which is why guidelines recommend offering screening regardless of ethnicity.
How CF Is Diagnosed
In the United States, all newborns are screened for CF shortly after birth through a blood test. If that initial screen is positive, a sweat test confirms or rules out the diagnosis. The sweat test measures chloride concentration in sweat, since defective CFTR channels cause abnormally salty sweat.
A chloride level of 60 mmol/L or higher indicates CF. A level between 30 and 59 mmol/L is considered borderline, and additional genetic testing is needed. A level below 29 mmol/L is normal. The test is painless and involves applying a small amount of chemical to the skin to stimulate sweating, then collecting the sweat on a gauze pad or coil.
Living With CF Today
Outcomes for people with CF have improved dramatically. Based on 2024 registry data from the Cystic Fibrosis Foundation, the median predicted survival age for someone born between 2020 and 2024 is 65 years. That figure was under 40 just two decades ago. The improvement is driven largely by CFTR modulator therapies, better airway clearance techniques, and earlier diagnosis through newborn screening.
Daily management still involves significant effort: airway clearance routines to loosen mucus, inhaled treatments, pancreatic enzyme supplements with meals, and close monitoring for lung infections. But for the majority of people with CF who are eligible for modulator therapy, lung function has stabilized or improved in ways that were unimaginable a generation ago. The disease remains serious, but being recessive and requiring two faulty gene copies means it can also be anticipated, tested for, and increasingly managed when it does occur.